Splash Beverage Group Acquires Exclusive Global Rights to CannEpil®, an Epilepsy Therapy with Established European Patient Access, FDA Engagement and U.S. Development Potential
Splash Beverage Group (NYSE American: SBEV) said it acquired exclusive worldwide licensing rights to Argent BioPharma’s CannEpil, a cannabinoid-based investigational therapy for drug-resistant epilepsy. The deal includes a $1M investment commitment from C/M Capital Partners and forgiveness of ~$5M debt by Mercer Street Global Opportunity Fund, plus $5.5M in SBEV preferred equity. Splash will pay a 15% royalty on net worldwide sales.
How this was made
The 30-second read
Why it matters
For SBEV, the transaction adds a potentially revenue-generating pipeline asset with a defined royalty structure (15% of net revenue to Argent) and a stated plan to advance FDA-related activities and expand evidence for U.S. development.
Market read
A new exclusive licensing deal with defined funding and regulatory pathway groundwork can drive near-term repricing of SBEV’s pipeline, but the real catalyst is execution toward U.S. clinical development and commercialization.
What to watch
Consider dilution/financing risk from issuing $5.5M preferred equity and the execution risk of building a U.S. clinical and commercialization partner network from a small platform.
Background
Splash Beverage Group announced an exclusive global licensing agreement for CannEpil, a cannabinoid-based investigational therapy for drug-resistant epilepsy, citing existing European patient access and FDA pre-IND/IND engagement.
Ticker impact
Splash (SBEV) secured exclusive worldwide rights to CannEpil and will issue preferred equity plus debt forgiveness to Argent BioPharma.
Likely positive near-term sentiment, but follow-through depends on FDA pathway progress and commercialization milestones.
The article discloses a new exclusive licensing agreement, a $1M strategic investment commitment, and specific consideration terms—inputs that can re-rate pipeline value, though no clinical efficacy or FDA decision is provided.
Market effects
Reinforces the trend of monetizing cannabinoid assets via licensing and U.S. regulatory pathway build-outs rather than early-stage R&D.
Highlights existing European patient-access/reimbursement frameworks that could inform U.S. evidence strategy.
Global exclusive rights and sublicensing potential may increase competitive focus on drug-resistant epilepsy cannabinoid therapeutics.
Counterpoint
The asset is still investigational for the U.S.; without disclosed U.S. clinical data or FDA milestones beyond pre-IND/IND assignment, the valuation uplift may be speculative.
Key entities
- public_companySplash Beverage Group, Inc.
NYSE American-listed acquirer of exclusive global rights to CannEpil and issuer of preferred equity as part of consideration.
- public_companyArgent BioPharma Limited
Licensor of CannEpil; receives a 15% royalty on worldwide net revenue and has indebtedness forgiven as part of the deal.
- investorC/M Capital Partners
Provides a $1M strategic investment commitment to support regulatory advancement and commercialization initiatives.
- investorMercer Street Global Opportunity Fund
Agreed to forgive approximately $5M of Argent BioPharma indebtedness as part of the transaction consideration.
- regulatorU.S. Food and Drug Administration (FDA)
Engaged via the pre-IND process; CannEpil has an assigned IND number per the release.
